Quick Facts

Holmes BioPharma, Inc.

• Comprised of knowledgeable management from the financial, pharmaceutical and biotech research sectors
• Proprietary capabilities with a strong existing client network base
• Offers multiple services in a wide scope of areas, both pharmaceutical and in research to provide recurring revenue streams
• Holmes' core business is focused in a vital industry reflected in double-digit annual growth
  
  

Qualia Clinical Services, Inc.

• Subsidiary of Holmes BioPharma, Inc.
• Contract Research Organization (CRO) located in Omaha, Nebraska, USA, Toronto, Canada and Kiev, Ukraine
• Providing outsourcing and partnership resources to pharmaceutical and biotech industries to facilitate drug development programs
• Executive team with over 75 years of industry experience
• Client-focused strategy that provides innovative and timely services
• Global network of facilities and partners to fully support drug development needs
  
  

Contract Research Organization Market

• CROs generate revenues of $68 billion USD per year (approximately $14 billion USD on Phase I studies)
• The R&D outsourcing market has grown from $5.4 billion in 1997 to $9.3 billion in 2001, representing an average annual growth rate of 14.6%.
• Incrementally a higher percentage of R&D spending will be outsourced over time to satisfy regulatory requirements for independent research results.
• Clinical study scheduling backlogs are often 6 to 9 months
• New drugs that entered clinical testing surged 52% in the past 3 years